Duchenne Muscular Dystrophy clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible males ages 12 years and up
This is a Phase 2, open-label, single arm trial of pamrevlumab (FG-3019) to estimate pamrevlumab's safety and efficacy in non-ambulatory subjects with DMD.
San Francisco, California and other locations